Skip to content
IGM Biosciences Logo
  • Home
  • About Us
  • Technology
  • Pipeline
    • IGM-2323: CD20 x CD3
    • IGM-8444: DR5
    • IGM-7354: IL-15 x PD-L1
    • Research & Discovery Programs
  • Team
    • Management
      • Fred M. Schwarzer, CEO
      • Bruce Keyt, CSO
      • Daniel S. Chen, CMO
      • Misbah Tahir, CFO
      • Lisa L. Decker, CBO
      • George A. Gauthier, CCO
      • Stephen F. Carroll, VP
      • Wayne Godfrey, VP
      • Paul Graffagnino, VP
      • Elizabeth Haanes, VP
      • Eric Humke, VP
      • Kathy Miller, VP
      • Marvin S. Peterson, VP
      • Angus M. Sinclair, VP
      • Suzette Tauber, VP
    • Board of Directors
    • Scientific Advisory Board
  • News
  • Presentations & Publications
  • Investors
  • Join Us
  • Contact Us
  • MENU

News

igm-news-hero-03

News

December, 2020

IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting

Read More...
November, 2020

IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting

Read More...
November, 2020

IGM Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Read More...
November, 2020

IGM Biosciences to Present at Three Upcoming Investor Conferences

Read More...
November, 2020

IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Read More...
November, 2020

IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting

Read More...
September, 2020

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s Lymphoma

Read More...
September, 2020

AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration

Read More...
September, 2020

IGM Biosciences to Present at Four Upcoming Investor Conferences

Read More...
August, 2020

IGM Biosciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Read More...
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
  • Home
  • About Us
  • Technology
  • Pipeline
    • IGM-2323: CD20 x CD3
    • IGM-8444: DR5
    • IGM-7354: IL-15 x PD-L1
    • Research & Discovery Programs
  • Team
    • Management
      • Fred M. Schwarzer, CEO
      • Bruce Keyt, CSO
      • Daniel S. Chen, CMO
      • Misbah Tahir, CFO
      • Lisa L. Decker, CBO
      • George A. Gauthier, CCO
      • Stephen F. Carroll, VP
      • Wayne Godfrey, VP
      • Paul Graffagnino, VP
      • Elizabeth Haanes, VP
      • Eric Humke, VP
      • Kathy Miller, VP
      • Marvin S. Peterson, VP
      • Angus M. Sinclair, VP
      • Suzette Tauber, VP
    • Board of Directors
    • Scientific Advisory Board
  • News
  • Presentations & Publications
  • Investors
  • Join Us
  • Contact Us

IGM Biosciences, Inc.
325 East Middlefield Road
Mountain View, CA 94043
(650) 965-7873
info@igmbio.com

All content © IGM Biosciences, Inc.

A SiteOrigin Theme